Antibacterial drugs are being elevated to blockbuster status as a new generation of lethal hospital-based superbugs prove resistant to standard therapies, according to a new report from Datamonitor. Community-based infections have always dominated this sector in the past, according to the new report, but drug-resistant superbugs in hospital settings-like MRSA-are changing that. Pfizer's Zyvox and Wyeth's Zosyn have already benefited from the trend and more therapies will be developed as an aging population helps trigger a continued surge in the superbug threat.
- read the UPI article on the Datamonitor report
Controversial cow drug nears FDA approval. Report
VA program slashes MRSA infection rates. Report
Study: Disinfectant cuts down on MRSA. Report